Antiangiogenic strategies in breast cancer management

Monica Giovannini, Daniela Aldrighetti, Patrizia Zucchinelli, Carmen Belli, Eugenio Villa

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Angiogenesis is considered one of the key mechanisms of tumour growth and survival. Therefore it represents an ideal pharmaceutical target. Many antiangiogenic agents have been developed so far in several solid tumours and also in breast cancer. Vascular endothelial growth factor (VEFG) is the main target and both monoclonal antibodies and small molecules belonging to the tyrosine kinase inhibitors directed against VEGF(R) have been developed. Some other therapeutic approaches have shown to exert some antiangiogenic activity, such as hormonal agents, metronomic chemotherapy, bisphosphonates and others. In this paper we provide an introduction of the current data supporting the angiogenesis in breast cancer and a review of the most relevant antiagiogenic therapies which have been investigated so far.

Original languageEnglish
Pages (from-to)13-35
Number of pages23
JournalCritical Reviews in Oncology/Hematology
Volume76
Issue number1
DOIs
Publication statusPublished - Oct 2010

Fingerprint

Vascular Endothelial Growth Factor A
Breast Neoplasms
Angiogenesis Inhibitors
Diphosphonates
Protein-Tyrosine Kinases
Neoplasms
Monoclonal Antibodies
Drug Therapy
Therapeutics
Growth
Pharmaceutical Preparations

Keywords

  • Antiangiogenic agents
  • Bisphosphonates
  • Breast cancer angiogenesis
  • COX-2 inhibitors
  • Hormonal therapy
  • Metronomic chemotherapy
  • Monoclonal antibodies
  • Tyrosin kinase inhibitors

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

Giovannini, M., Aldrighetti, D., Zucchinelli, P., Belli, C., & Villa, E. (2010). Antiangiogenic strategies in breast cancer management. Critical Reviews in Oncology/Hematology, 76(1), 13-35. https://doi.org/10.1016/j.critrevonc.2009.12.004

Antiangiogenic strategies in breast cancer management. / Giovannini, Monica; Aldrighetti, Daniela; Zucchinelli, Patrizia; Belli, Carmen; Villa, Eugenio.

In: Critical Reviews in Oncology/Hematology, Vol. 76, No. 1, 10.2010, p. 13-35.

Research output: Contribution to journalArticle

Giovannini, M, Aldrighetti, D, Zucchinelli, P, Belli, C & Villa, E 2010, 'Antiangiogenic strategies in breast cancer management', Critical Reviews in Oncology/Hematology, vol. 76, no. 1, pp. 13-35. https://doi.org/10.1016/j.critrevonc.2009.12.004
Giovannini, Monica ; Aldrighetti, Daniela ; Zucchinelli, Patrizia ; Belli, Carmen ; Villa, Eugenio. / Antiangiogenic strategies in breast cancer management. In: Critical Reviews in Oncology/Hematology. 2010 ; Vol. 76, No. 1. pp. 13-35.
@article{767d50d5edfb4cf1a4aa373cffd6e804,
title = "Antiangiogenic strategies in breast cancer management",
abstract = "Angiogenesis is considered one of the key mechanisms of tumour growth and survival. Therefore it represents an ideal pharmaceutical target. Many antiangiogenic agents have been developed so far in several solid tumours and also in breast cancer. Vascular endothelial growth factor (VEFG) is the main target and both monoclonal antibodies and small molecules belonging to the tyrosine kinase inhibitors directed against VEGF(R) have been developed. Some other therapeutic approaches have shown to exert some antiangiogenic activity, such as hormonal agents, metronomic chemotherapy, bisphosphonates and others. In this paper we provide an introduction of the current data supporting the angiogenesis in breast cancer and a review of the most relevant antiagiogenic therapies which have been investigated so far.",
keywords = "Antiangiogenic agents, Bisphosphonates, Breast cancer angiogenesis, COX-2 inhibitors, Hormonal therapy, Metronomic chemotherapy, Monoclonal antibodies, Tyrosin kinase inhibitors",
author = "Monica Giovannini and Daniela Aldrighetti and Patrizia Zucchinelli and Carmen Belli and Eugenio Villa",
year = "2010",
month = "10",
doi = "10.1016/j.critrevonc.2009.12.004",
language = "English",
volume = "76",
pages = "13--35",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Antiangiogenic strategies in breast cancer management

AU - Giovannini, Monica

AU - Aldrighetti, Daniela

AU - Zucchinelli, Patrizia

AU - Belli, Carmen

AU - Villa, Eugenio

PY - 2010/10

Y1 - 2010/10

N2 - Angiogenesis is considered one of the key mechanisms of tumour growth and survival. Therefore it represents an ideal pharmaceutical target. Many antiangiogenic agents have been developed so far in several solid tumours and also in breast cancer. Vascular endothelial growth factor (VEFG) is the main target and both monoclonal antibodies and small molecules belonging to the tyrosine kinase inhibitors directed against VEGF(R) have been developed. Some other therapeutic approaches have shown to exert some antiangiogenic activity, such as hormonal agents, metronomic chemotherapy, bisphosphonates and others. In this paper we provide an introduction of the current data supporting the angiogenesis in breast cancer and a review of the most relevant antiagiogenic therapies which have been investigated so far.

AB - Angiogenesis is considered one of the key mechanisms of tumour growth and survival. Therefore it represents an ideal pharmaceutical target. Many antiangiogenic agents have been developed so far in several solid tumours and also in breast cancer. Vascular endothelial growth factor (VEFG) is the main target and both monoclonal antibodies and small molecules belonging to the tyrosine kinase inhibitors directed against VEGF(R) have been developed. Some other therapeutic approaches have shown to exert some antiangiogenic activity, such as hormonal agents, metronomic chemotherapy, bisphosphonates and others. In this paper we provide an introduction of the current data supporting the angiogenesis in breast cancer and a review of the most relevant antiagiogenic therapies which have been investigated so far.

KW - Antiangiogenic agents

KW - Bisphosphonates

KW - Breast cancer angiogenesis

KW - COX-2 inhibitors

KW - Hormonal therapy

KW - Metronomic chemotherapy

KW - Monoclonal antibodies

KW - Tyrosin kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=77956618636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956618636&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2009.12.004

DO - 10.1016/j.critrevonc.2009.12.004

M3 - Article

VL - 76

SP - 13

EP - 35

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 1

ER -